CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
Immediate release sodium nitrite +2 moredrug
Likely dose
Immediate release sodium nitrite 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02552888
NCT02552888Phase 2Completed
CompareCT.gov

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

Tulane University·interventional·Posted Sep 17, 2015·Updated Apr 20, 2021

In Brief

A Phase 2 clinical trial evaluating Immediate release sodium nitrite, Isoquercetin, and 1 other intervention for Chronic Kidney Disease. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsNational Institute of General Medical Sciences (NIGMS)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 17, 2015
Enrollment StartMar 1, 2016
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.8 years ago

Interventions

Immediate release sodium nitritedrug

Immediate release sodium nitrite 40 mg by mouth twice per day

Isoquercetindietary

Isoquercetin 225 mg by mouth once per day

placebosother

placebos